These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 33344042)

  • 1. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
    de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
    Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
    Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
    Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.
    Figueiredo CR; Azevedo RA; Mousdell S; Resende-Lara PT; Ireland L; Santos A; Girola N; Cunha RLOR; Schmid MC; Polonelli L; Travassos LR; Mielgo A
    Front Immunol; 2018; 9():1132. PubMed ID: 29875777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.
    Valdez CN; Sánchez-Zuno GA; Osmani L; Ibrahim W; Galan A; Bacchiocchi A; Halaban R; Kulkarni RP; Kang I; Bucala R; Tran T
    Oncotarget; 2024 Jul; 15():507-520. PubMed ID: 39028303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-32γ potentiates tumor immunity in melanoma.
    Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy.
    Fey RM; Nichols RA; Tran TT; Vandenbark AA; Kulkarni RP
    Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.
    Tanese K; Hashimoto Y; Berkova Z; Wang Y; Samaniego F; Lee JE; Ekmekcioglu S; Grimm EA
    J Invest Dermatol; 2015 Nov; 135(11):2775-2784. PubMed ID: 26039541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic use attenuates response to immune checkpoint blockade in urothelial carcinoma via inhibiting CD74-MIF/COPA: revealing cross-talk between anti-bacterial immunity and anti-tumor immunity through a tumor marker prognostic study.
    Song Y; Peng Y; Qin C; Jiang S; Lin J; Lai S; Wu J; Ding M; Du Y; Yu L; Xu T
    Int J Surg; 2024 Jul; ():. PubMed ID: 38995167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies.
    Wei S; Du K; Lan H; Yang Z; Deng Y; Wei Z; Frederick DT; Lee J; Labrie M; Tian T; Moll T; Chen Y; Sullivan RJ; Mills G; Boland GM; Flaherty KT; Liu L; Herlyn M; Zhang G
    bioRxiv; 2024 Sep; ():. PubMed ID: 39314469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant
    Jeong H; Lee SY; Seo H; Kim BJ
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
    De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
    Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion.
    Yan L; Wu M; Wang T; Yuan H; Zhang X; Zhang H; Li T; Pandey V; Han X; Lobie PE; Zhu T
    Cancer Res; 2024 Apr; 84(8):1270-1285. PubMed ID: 38335272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targetted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance.
    Chan PC; Wu TN; Chen YC; Lu CH; Wabitsch M; Tian YF; Hsieh PS
    Clin Sci (Lond); 2018 Jul; 132(14):1581-1596. PubMed ID: 29773671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.